# Study of the Safety and Efficacy of Intravenous Alpha-1 Antitrypsin in Type 1 Diabetes Mellitus

> **NCT01304537** · PHASE1,PHASE2 · COMPLETED · sponsor: **Kamada, Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** Alpha-1 Antitrypsin 40mg (AAT, Glassia®)
- **DRUG:** Alpha-1 Antitrypsin 60mg (AAT, Glassia®)
- **DRUG:** Alpha-1 Antitrypsin 80mg (AAT, Glassia®)

## Key facts

- **NCT ID:** NCT01304537
- **Lead sponsor:** Kamada, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2016-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01304537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01304537, "Study of the Safety and Efficacy of Intravenous Alpha-1 Antitrypsin in Type 1 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01304537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*